SUMMARY
Ropivacaine (1'-propyl-2',6'-pipecoloxylidide) is a new medium-to long-acting local anaesthetic of the amino amide class. Its chemical structure is similar to that of bupivacaine and mepivacaine, differing from bupivacaine by the substitution of a propyl group for the butyl side-chain. Uniquely amongst local anaesthetics, ropivacaine is produced as the pure S(-) enantiomer rather than a racemic mixture. The S-enantiomer has been shown to produce peripheral nerve anaesthesia of longer duration than either the racemate or the R-form 1 . In addition, ropivacaine has been shown to have vasoconstrictor properties 2 . Animal and human studies suggest that ropivacaine possesses less potential for cardiac and central nervous system toxicity than bupivacaine. The question then arises as to the relative anaesthetic characteristics produced by the two agents. If ropivacaine was shown to be a less potent or shorteracting local anaesthetic than bupivacaine, then any attempt to increase its clinical efficacy by using greater doses or higher concentrations might compromise its relative advantage regarding safety.
This study was performed to compare the anaesthetic characteristics of 0.5% ropivacaine with that of LUMBAR EPIDURAL ROPIVACAINE Anaesthesia and Intensive Care, Vol. 25, No. 3, June 1997 0.5% bupivacaine when administered epidurally in equal doses for lower limb orthopaedic surgery.
METHODS
A randomized, double-blind multi-centre trial comparing epidural ropivacaine 0.5% and bupivacaine 0.5% was carried out in 67 patients undergoing lower limb orthopaedic surgery. The trial involved three institutions and was approved by the Ethics Committees of each participating centre. Written informed consent was obtained from each patient. Patients included in the study were at least 18 years old, ASA status 1-3, and weight 60-90 kg. Excluded were pregnant women or those of childbearing potential, patients with current problems of drug or alcohol abuse and those patients taking beta adrenergic blocking medication. The study solutions were manufactured by Astra Pain Control AB, Södertälje, Sweden, and were supplied in identically appearing 20 ml glass ampoules. Patient randomization was by a computer-generated random number sequence and performed in blocks so that there was equal probability of a patient receiving either study solution.
Premedication consisted of oral temazepam 10-20 mg administered 30-90 minutes preoperatively. All concurrent medications were administered as appropriate. Prior to the block insertion, an intravenous infusion of Hartmann's solution was commenced and all patients were preloaded with 500 to 1000 ml. Midazolam was given intravenously if supplemental sedation was required. Automated non-invasive blood pressure monitoring and pulse oximetry were used during block insertion.
Following skin infiltration with 1% lignocaine, the epidural space was identified using loss of resistance at either the L2,3 or L3,4 interspace in the midline with a 16 or 18 gauge Tuohy needle. With the bevel of the needle directed cranially, a 3 ml dose of the study solution was administered and then a catheter inserted through the needle 3-5 cm into the epidural space. The patient was then placed supine and a further 17 ml of the study drug was administered over a three-to five-minute period. All patients received 100 mg of the study drug.
Sensory and motor block were assessed at 2, 5, 10, 15, 20 and 30 minutes post injection, at 30-minute intervals for the next five hours, and then every two hours thereafter until there was return of normal motor and sensory function. Motor block was assessed by using the Bromage scale (0=no motor block, 1=inability to raise the extended leg, 2=in-ability to flex the knee, 3=complete motor block), and sensory analgesia was assessed by the blunt end of a 27 gauge Carpule® dental needle (Bayer). At the end of the case, the quality of the anaesthesia, both motor and sensory, was judged as either satisfactory or unsatisfactory. Heart rate and blood pressure were recorded prior to administration of the epidural, and at five-minute intervals thereafter for 45 minutes.
If there was a total failure to achieve an epidural block, this was classed as a technical failure, and the patient withdrawn from the study and replaced by the next available patient. In the event of inadequate analgesia at the site of surgery, the patient received another anaesthetic technique at the discretion of the anaesthetist. If this was an epidural top-up, the patient was excluded from further analysis beyond that time. If general anaesthesia was induced and it was possible to observe regression times after the patient had woken up, these observations were included.
Statistics: Interval data (onset and duration of analgesia and motor block) were analysed using analysis of variance (ANOVA) and presented as mean± standard error. If the residuals of the ANOVA were non-normal, Mantel-Haenszel methods were used and non-parametric confidence intervals expressed (median±range) 3 . Dichotomous data (frequency of motor block) and ordinal data (segmental level of analgesia) were analysed using Mantel-Haenszel methods. All tests were two-tailed and a P value of less than 0.05 was considered statistically significant.
RESULTS
Sixty-seven patients were enrolled in the study, 32 of whom received ropivacaine and 35 bupivacaine. The patients were similar regarding age, height, weight, sex and ASA status (Table 1) . Four patients (3 ropivacaine, 1 bupivacaine) who achieved no demonstrable local anaesthetic block, were classed as technical failures and therefore excluded from the study. Two patients in the ropivacaine group received a general anaesthetic prior to the commencement of surgery because of slow block onset, leaving 27 patients for further analysis. Another six patients (2 ropivacaine, 4 bupivacaine) received general anaesthesia at some stage during the procedure because of inadequate surgical anaesthesia or patient restlessness. Ten patients (6 bupivacaine, 4 ropivacaine) received an epidural top-up at some stage during the procedure because of inadequate surgical anaesthesia and were excluded from further analysis. The duration of surgery (mean, range) was 78 (16-210) minutes in the ropivacaine group and 82 (15-172) minutes in the bupivacaine group.
Sensory Analgesia
The onset time and duration of segmental analgesia are shown in Figures 1 and 2 . There was no significant difference between the two treatment groups. Table 2 shows the onset time, duration and regression of sensory analgesia at levels considered suitable for surgery (T10-S3). These results were similar in both groups. The median upper dermatome level was T6 (range T2-T12) in the ropivacaine group and T5 (range C7-T10) in the bupivacaine group. Block of the S3 dermatome was achieved in all but four patients in the ropivacaine group and three in the bupivacaine group. Table 3 shows the onset and duration and frequencies of the various grades of motor block in each group. There was no significant difference between the two treatment groups in the frequency of motor block at the hip, knee or ankle. There was no significant difference regarding the duration of motor block at the hip, knee or ankle although the median values were all greater with bupivacaine.
Motor Block

Quality of Surgical Anaesthesia
Sensory analgesia was satisfactory in 78% of the ropivacaine group and 62% of the bupivacaine group. Motor block was satisfactory in 78% ropivacaine and 71% bupivacaine patients. These differences were not significant.
Cardiovascular Effects
The cardiovascular profile over the first 45 minutes was similar between the two treatment groups with no significant differences observed (Figures 3, 4) . FIGURE 1: The onset times for segmental sensory analgesia at various dermatome levels (median±interquartile range).
FIGURE 2: The duration of sensory segmental analgesia at various dermatome levels (median±interquartile range). 
DISCUSSION
The present study assessed the anaesthetic properties of 0.5% ropivacaine and 0.5% bupivacaine in equal volumes when administered epidurally in humans. The two agents produced a similar anaesthetic profile in terms of sensory analgesia, quality of anaesthesia and effects upon the cardiovascular system. The numbers who had motor block at the hip, knee and ankle were also similar with the two agents. The duration of motor block produced by bupivacaine tended to be longer than that produced by ropivacaine, although the difference was not statistically significant.
Concerns may be raised regarding the success rate of anaesthesia in this study. In the ropivacaine group (n=27), sensory and motor block were considered satisfactory in 21 patients (78%). In the bupivacaine group (n=34), sensory block and motor block were satisfactory in 21 (62%) and in 24 (71%) patients respectively. These results are reflected in the number of intraoperative anaesthetic interventions performed in each group (ropivacaine: 2 general anaesthesias, 2 epidural top-ups; bupivacaine: 4 general anaesthesias, 5 epidural top-ups), and may be indicative of the limitations of the study rather than a reflection on the anaesthetic characteristics of either drug. The study design required all patients to receive a fixed dose of either agent (20 ml) irrespective of individual height, weight or age. In clinical practice, inadequacies of the quality of epidural anaesthesia indicate further local anaesthetic administration. With either agent it may be expected that greater degrees of success and satisfaction would be achieved with flexibility and titration of the local anaesthetic dose. The greater safety margin provided by ropivacaine might allow the use of higher concentrations of solution in order to provide more satisfactory anaesthetic conditions. While we were unable to demonstrate any significant clinical differences between the two agents, previous work comparing their use epidurally has found inconsistent differences. A number of studies have been unable to demonstrate a difference in the onset or spread of sensory block produced by equal doses of either agent [4] [5] [6] [7] , although Kerkkamp 4 and Brown 5 found a longer duration of sensory block with bupivacaine. Our study was unable to demonstrate a significant difference in the motor block produced by the two agents. This has also been the conclusion of previous studies by Brown 5 and Wolff 8 . Others have found that the motor block produced by ropivacaine is usually less intense and of shorter duration than that from bupivacaine 4, 6, 7 . While dense motor block is usually desirable during surgery, a less intense motor block may be an advantage in certain situations such as in obstetric or postoperative epidural analgesia 9 . In an attempt to produce more consistent anaesthesia and motor block, the higher concentrations of 0.75% and 1% ropivacaine have been produced. Increasing the concentration of ropivacaine has not been shown to affect the speed of block onset, but on an equal volume basis has usually produced more profound and longer-lasting motor block and an increased duration of sensory block [10] [11] [12] . Animal data suggest that the cardiac and central nervous system toxicity of ropivacaine is approximately half that of bupivacaine 13, 14 . Increasing the concentration of ropivacaine in an attempt to improve the quality of surgical anaesthesia could increase the toxic potential and thereby offset its main clinical advantage over bupivacaine, if the volume administered, and hence the actual dose, is not adjusted appropriately.
In summary, this study has not demonstrated any significant differences between the clinical effects produced by epidural ropivacaine 0.5% or bupivacaine 0.5%.
